论文部分内容阅读
目的:探讨功能性鼻窦内镜手术(FESS)术后应用普米克令舒鼻雾化吸入的近期疗效。方法:44例慢性鼻窦炎(Ⅱ型Ⅱ期)患者,均行FESS,21例患者(治疗组)术后第2天开始鼻雾化吸入普米克令舒共10d,另23例患者(对照组)术后常规用雷诺考特喷鼻。2组患者均于术后第2天及第14天行临床症状和体征评分,第14天同时行鼻内镜下术腔上颌窦窦口黏膜活检,显微镜下计数每百个炎性细胞中嗜酸粒细胞和中性粒细胞的数量,统计2组患者症状体征总分值及总有效率有无统计学意义,以及嗜酸粒细胞和中性粒细胞计数百分比有无统计学意义。结果:2组患者术后第2天总分值差异无统计学意义,第14天治疗组总分值低于对照组(P<0.01),总有效率高于对照组,但差异无统计学意义(P>0.05);2组嗜酸粒细胞计数差异无统计学意义(P>0.05),中性粒细胞计数治疗组低于对照组(P<0.01)。结论:普米克令舒配合PARISINUS鼻雾化吸入器使用,能够充分到达上颌窦窦腔内,其作用面积更广泛,起效更快,控制急性炎症感染的效果更好,在FESS术后应用,能明显减轻患者急性炎症和水肿反应,减少黏膜水肿、术腔粘连和窦口狭窄等并发症,其近期疗效优于鼻喷雾剂型的同类药物。
Objective: To explore the short-term effect of inhalation of Pulmicort respules after functional sinus surgery (FESS). Methods: Forty-four patients with chronic sinusitis (type Ⅱ stage Ⅱ) underwent FESS. 21 patients (treatment group) received primed amikacin for 10 days on the second day after operation, and 23 patients (control group ) Routine routine use Renault exam nasal spray. The patients in both groups underwent clinical symptoms and signs on the second and the fourteenth day after operation. On the fourteenth day, the patients underwent endoscopic sinus mucosa biopsy of the maxillary sinus under the endoscope, and the counts of perilitis The number of acid granulocytes and neutrophils, statistical group 2 patients with total score of symptoms and signs and the total effective rate was no statistical significance, and the percentage of eosinophils and neutrophils count was statistically significant. Results: There was no significant difference between the two groups on the second day after operation. The total score of the 14th day in the treatment group was lower than that in the control group (P <0.01), and the total effective rate was higher than that in the control group, but the difference was not statistically significant (P> 0.05). There was no significant difference in eosinophil count between the two groups (P> 0.05). The neutrophil count was lower in the treatment group than in the control group (P <0.01). CONCLUSION: Pulmicort respirator combined with PARISINUS nasal inhaler can reach the sinus cavity of the maxillary sinus with a wider area of action, faster onset of action and better control of acute inflammatory infection. After FESS operation, Can significantly reduce the patient’s acute inflammation and edema response, reduce mucosal edema, intraluminal adhesions and sinus stenosis and other complications, its immediate effect is better than the nasal spray-type of similar drugs.